Active, not recruitingPhase 2NCT06056895

Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma

Studying Cutaneous neuroendocrine carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Washington
Principal Investigator
Shailender Bhatia, MD
Fred Hutch/University of Washington Cancer Consortium
Intervention
Biopsy(procedure)
Enrollment
12 enrolled
Eligibility
18 years · All sexes
Timeline
20232027

Study locations (1)

Collaborators

Incyte Corporation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06056895 on ClinicalTrials.gov

Other trials for Cutaneous neuroendocrine carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cutaneous neuroendocrine carcinoma

← Back to all trials